nach oben

Cancer and Metastasis Reviews

Erschienen in:

01.12.2010 | NON-THEMATIC REVIEW

DNA repair pathways and their implication in cancer treatment

verfasst von: Athanasios G. Pallis, Michalis V. Karamouzis

Erschienen in: Cancer and Metastasis Reviews | Ausgabe 4/2010

Einloggen, um Zugang zu erhalten

Abstract

Many cytotoxic agents used in cancer treatment exert their effects through their ability to directly or indirectly damage DNA and thus resulting in cell death. Major types of DNA damage induced by anticancer treatment include strand breaks (double or single strand), crosslinks (inter-strand, intra-strand, DNA–protein crosslinks), and interference with nucleotide metabolism and DNA synthesis. On the other hand, cancer cells activate various DNA repair pathways and repair DNA damages induced by cytotoxic drugs. The purpose of the current review is to present the major types of DNA damage induced by cytotoxic agents, DNA repair pathways, and their role as predictive agents, as well as evaluate the future perspectives of the novel DNA repair pathways inhibitors in cancer therapeutics.

Vermund, H., & Gollin, F. F. (1968). Mechanisms of action of radiotherapy and chemotherapeutic adjuvants. A review. Cancer, 21, 58–76.CrossRefPubMed

Longley, D. B., & Johnston, P. G. (2005). Molecular mechanisms of drug resistance. The Journal of Pathology, 205, 275–292.CrossRefPubMed

Khanna, K. K., & Jackson, S. P. (2001). DNA double-strand breaks: Signaling, repair and the cancer connection. Nature Genetics, 27, 247–254.CrossRefPubMed

Caldecott, K. W. (2008). Single-strand break repair and genetic disease. Nature Reviews Genetics, 9, 619–631.PubMed

Hurley, L. H. (2002). DNA and its associated processes as targets for cancer therapy. Nature Reviews Cancer, 2, 188–200.CrossRefPubMed

Hakem, R. (2008). DNA-damage repair; the good, the bad, and the ugly. The EMBO Journal, 27, 589–605.CrossRefPubMed

Olaussen, K. A., Dunant, A., Fouret, P., Brambilla, E., Andre, F., Haddad, V., et al. (2006). DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. The New England Journal of Medicine, 355, 983–991.CrossRefPubMed

Pallis, A. G., Serfass, L., Dziadziusko, R., van Meerbeeck, J. P., Fennell, D., Lacombe, D., et al. (2009). Targeted therapies in the treatment of advanced/metastatic NSCLC. European Journal of Cancer, 45, 2473–2487.CrossRefPubMed

Sedgwick, B., Bates, P. A., Paik, J., Jacobs, S. C., & Lindahl, T. (2007). Repair of alkylated DNA: Recent advances. DNA Repair (Amst), 6, 429–442.CrossRef

10.

Middleton, M. R., & Margison, G. P. (2003). Improvement of chemotherapy efficacy by inactivation of a DNA-repair pathway. The Lancet Oncology, 4, 37–44.CrossRefPubMed

11.

Sharma, S., Salehi, F., Scheithauer, B. W., Rotondo, F., Syro, L. V., & Kovacs, K. (2009). Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Research, 29, 3759–3768.PubMed

12.

Leibeling, D., Laspe, P., & Emmert, S. (2006). Nucleotide excision repair and cancer. Journal of Molecular Histology, 37, 225–238.CrossRefPubMed

13.

Hanawalt, P. C. (2002). Subpathways of nucleotide excision repair and their regulation. Oncogene, 21, 8949–8956.CrossRefPubMed

14.

de Laat, W. L., Jaspers, N. G., & Hoeijmakers, J. H. (1999). Molecular mechanism of nucleotide excision repair. Genes & Development, 13, 768–785.CrossRef

15.

Aboussekhra, A., Biggerstaff, M., Shivji, M. K., Vilpo, J. A., Moncollin, V., Podust, V. N., et al. (1995). Mammalian DNA nucleotide excision repair reconstituted with purified protein components. Cell, 80, 859–868.CrossRefPubMed

16.

van Steeg, H., & Kraemer, K. H. (1999). Xeroderma pigmentosum and the role of UV-induced DNA damage in skin cancer. Molecular Medicine Today, 5, 86–94.CrossRefPubMed

17.

Niedernhofer, L. J., Odijk, H., Budzowska, M., van Drunen, E., Maas, A., Theil, A. F., et al. (2004). The structure-specific endonuclease Ercc1-Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Molecular and Cellular Biology, 24, 5776–5787.CrossRefPubMed

18.

Sharma, R. A., & Dianov, G. L. (2007). Targeting base excision repair to improve cancer therapies. Molecular Aspects of Medicine, 28, 345–374.CrossRefPubMed

19.

Chan, K. K., Zhang, Q. M., & Dianov, G. L. (2006). Base excision repair fidelity in normal and cancer cells. Mutagenesis, 21, 173–178.CrossRefPubMed

20.

Wilson, D. M., III, & Bohr, V. A. (2007). The mechanics of base excision repair, and its relationship to aging and disease. DNA Repair (Amst), 6, 544–559.CrossRef

21.

Ame, J. C., Spenlehauer, C., & de Murcia, G. (2004). The PARP superfamily. Bioessays, 26, 882–893.CrossRefPubMed

22.

Min, W., & Wang, Z. Q. (2009). Poly (ADP-ribose) glycohydrolase (PARG) and its therapeutic potential. Frontiers in Bioscience, 14, 1619–1626.CrossRefPubMed

23.

Hoeijmakers, J. H. (2001). Genome maintenance mechanisms for preventing cancer. Nature, 411, 366–374.CrossRefPubMed

24.

Malanga, M., & Althaus, F. R. (2005). The role of poly(ADP-ribose) in the DNA damage signaling network. Biochemistry and Cell Biology, 83, 354–364.CrossRefPubMed

25.

Chalmers, A. J. (2009). The potential role and application of PARP inhibitors in cancer treatment. British Medical Bulletin, 89, 23–40.CrossRefPubMed

26.

Jiricny, J. (2006). The multifaceted mismatch-repair system. Nature Reviews Molecular Cell Biology, 7, 335–346.CrossRefPubMed

27.

Li, G. M. (2008). Mechanisms and functions of DNA mismatch repair. Cell Research, 18, 85–98.CrossRefPubMed

28.

Sonoda, E., Hochegger, H., Saberi, A., Taniguchi, Y., & Takeda, S. (2006). Differential usage of non-homologous end-joining and homologous recombination in double strand break repair. DNA Repair (Amst), 5, 1021–1029.CrossRef

29.

Lieber, M. R. (2008). The mechanism of human nonhomologous DNA end joining. The Journal of Biological Chemistry, 283, 1–5.CrossRefPubMed

30.

Johnson, R. D., & Jasin, M. (2001). Double-strand-break-induced homologous recombination in mammalian cells. Biochemical Society Transactions, 29, 196–201.CrossRefPubMed

31.

Andegeko, Y., Moyal, L., Mittelman, L., Tsarfaty, I., Shiloh, Y., & Rotman, G. (2001). Nuclear retention of ATM at sites of DNA double strand breaks. The Journal of Biological Chemistry, 276, 38224–38230.PubMed

32.

Bassing, C. H., & Alt, F. W. (2004). The cellular response to general and programmed DNA double strand breaks. DNA Repair (Amst), 3, 781–796.CrossRef

33.

Sabharwal, A., & Middleton, M. R. (2006). Exploiting the role of O6-methylguanine-DNA-methyltransferase (MGMT) in cancer therapy. Current Opinion in Pharmacology, 6, 355–363.CrossRefPubMed

34.

Gerson, S. L. (2004). MGMT: Its role in cancer aetiology and cancer therapeutics. Nature Reviews Cancer, 4, 296–307.CrossRefPubMed

35.

Esteller, M., Hamilton, S. R., Burger, P. C., Baylin, S. B., & Herman, J. G. (1999). Inactivation of the DNA repair gene O6-methylguanine-DNA methyltransferase by promoter hypermethylation is a common event in primary human neoplasia. Cancer Research, 59, 793–797.PubMed

36.

Esteller, M., Garcia-Foncillas, J., Andion, E., Goodman, S. N., Hidalgo, O. F., Vanaclocha, V., et al. (2000). Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. The New England Journal of Medicine, 343, 1350–1354.CrossRefPubMed

37.

Jaeckle, K. A., Eyre, H. J., Townsend, J. J., Schulman, S., Knudson, H. M., Belanich, M., et al. (1998). Correlation of tumor O6 methylguanine-DNA methyltransferase levels with survival of malignant astrocytoma patients treated with bis-chloroethylnitrosourea: A Southwest Oncology Group study. Journal of Clinical Oncology, 16, 3310–3315.PubMed

38.

Hegi, M. E., Diserens, A. C., Godard, S., Dietrich, P. Y., Regli, L., Ostermann, S., et al. (2004). Clinical trial substantiates the predictive value of O-6-methylguanine-DNA methyltransferase promoter methylation in glioblastoma patients treated with temozolomide. Clinical Cancer Research, 10, 1871–1874.CrossRefPubMed

39.

Paz, M. F., Yaya-Tur, R., Rojas-Marcos, I., Reynes, G., Pollan, M., Guirre-Cruz, L., et al. (2004). CpG island hypermethylation of the DNA repair enzyme methyltransferase predicts response to temozolomide in primary gliomas. Clinical Cancer Research, 10, 4933–4938.CrossRefPubMed

40.

van den Bent, M. J., Dubbink, H. J., Sanson, M., van der Lee-Haarloo, C. R., Hegi, M., Jeuken, J. W., et al. (2009). MGMT promoter methylation is prognostic but not predictive for outcome to adjuvant PCV chemotherapy in anaplastic oligodendroglial tumors: A report from EORTC Brain Tumor Group Study 26951. Journal of Clinical Oncology, 27, 5881–5886.CrossRefPubMed

41.

Simon, G. R., Sharma, S., Cantor, A., Smith, P., & Bepler, G. (2005). ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest, 127, 978–983.CrossRefPubMed

42.

Lord, R. V., Brabender, J., Gandara, D., Alberola, V., Camps, C., Domine, M., et al. (2002). Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clinical Cancer Research, 8, 2286–2291.PubMed

43.

Shirota, Y., Stoehlmacher, J., Brabender, J., Xiong, Y. P., Uetake, H., Danenberg, K. D., et al. (2001). ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. Journal of Clinical Oncology, 19, 4298–4304.PubMed

44.

Dabholkar, M., Vionnet, J., Bostick-Bruton, F., Yu, J. J., & Reed, E. (1994). Messenger RNA levels of XPAC and ERCC1 in ovarian cancer tissue correlate with response to platinum-based chemotherapy. The Journal of Clinical Investigation, 94, 703–708.CrossRefPubMed

45.

Metzger, R., Leichman, C. G., Danenberg, K. D., Danenberg, P. V., Lenz, H. J., Hayashi, K., et al. (1998). ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. Journal of Clinical Oncology, 16, 309–316.PubMed

46.

Welsh, C., Day, R., McGurk, C., Masters, J. R., Wood, R. D., & Koberle, B. (2004). Reduced levels of XPA, ERCC1 and XPF DNA repair proteins in testis tumor cell lines. International Journal of Cancer, 110, 352–361.CrossRef

47.

Stevens, E. V., Raffeld, M., Espina, V., Kristensen, G. B., Trope’, C. G., Kohn, E. C., et al. (2005). Expression of xeroderma pigmentosum A protein predicts improved outcome in metastatic ovarian carcinoma. Cancer, 103, 2313–2319.CrossRefPubMed

48.

Starostik, P., Manshouri, T., O’Brien, S., Freireich, E., Kantarjian, H., Haidar, M., et al. (1998). Deficiency of the ATM protein expression defines an aggressive subgroup of B-cell chronic lymphocytic leukemia. Cancer Research, 58, 4552–4557.PubMed

49.

Korabiowska, M., Tscherny, M., Grohmann, U., Honig, J. F., Bartkowski, S. B., Cordon-Cardo, C., et al. (2002). Decreased expression of Ku70/Ku80 proteins in malignant melanomas of the oral cavity. Anticancer Research, 22, 193–196.PubMed

50.

Komuro, Y., Watanabe, T., Hosoi, Y., Matsumoto, Y., Nakagawa, K., Tsuno, N., et al. (2002). The expression pattern of Ku correlates with tumor radiosensitivity and disease free survival in patients with rectal carcinoma. Cancer, 95, 1199–1205.CrossRefPubMed

51.

Komuro, Y., Watanabe, T., Hosoi, Y., Matsumoto, Y., Nakagawa, K., Saito, S., et al. (2003). Prediction of tumor radiosensitivity in rectal carcinoma based on p53 and Ku70 expression. Journal of Experimental & Clinical Cancer Research, 22, 223–228.

52.

Komuro, Y., Watanabe, T., Hosoi, Y., Matsumoto, Y., Nakagawa, K., Suzuki, N., et al. (2005). Prognostic significance of Ku70 protein expression in patients with advanced colorectal cancer. Hepatogastroenterology, 52, 995–998.PubMed

53.

Brooks, K. R., To, K., Joshi, M. B., Conlon, D. H., Herndon, J. E., D’Amico, T. A., et al. (2003). Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: A novel approach for patient selection. The Annals of Thoracic Surgery, 76, 187–193.CrossRefPubMed

54.

Taubert, H. W., Bartel, F., Kappler, M., Schuster, K., Meye, A., Lautenschlager, C., et al. (2003). Reduced expression of hMSH2 protein is correlated to poor survival for soft tissue sarcoma patients. Cancer, 97, 2273–2278.CrossRefPubMed

55.

Nakata, B., Wang, Y. Q., Yashiro, M., Ohira, M., Ishikawa, T., Nishino, H., et al. (2003). Negative hMSH2 protein expression in pancreatic carcinoma may predict a better prognosis of patients. Oncology Reports, 10, 997–1000.PubMed

56.

Catto, J. W., Xinarianos, G., Burton, J. L., Meuth, M., & Hamdy, F. C. (2003). Differential expression of hMLH1 and hMSH2 is related to bladder cancer grade, stage and prognosis but not microsatellite instability. International Journal of Cancer, 105, 484–490.CrossRef

57.

Son, B. H., Ahn, S. H., Ko, C. D., Ka, I. W., Gong, G. Y., & Kim, J. C. (2004). Significance of mismatch repair protein expression in the chemotherapeutic response of sporadic invasive ductal carcinoma of the breast. The Breast Journal, 10, 20–26.CrossRefPubMed

58.

Arabi, H., Guan, H., Kumar, S., Cote, M., Bandyopadhyay, S., Bryant, C., et al. (2009). Impact of microsatellite instability (MSI) on survival in high grade endometrial carcinoma. Gynecological Oncology, 113, 153–158.CrossRef

59.

Bilbao, C., Lara, P. C., Ramirez, R., Henriquez-Hernandez, L. A., Rodriguez, G., Falcon, O., et al. (2010). Microsatellite instability predicts clinical outcome in radiation-treated endometrioid endometrial cancer. International Journal of Radiation Oncology, Biology, Physics, 76, 9–13.PubMed

60.

Des, G. G., Schischmanoff, O., Nicolas, P., Perret, G. Y., Morere, J. F., & Uzzan, B. (2009). Does microsatellite instability predict the efficacy of adjuvant chemotherapy in colorectal cancer? A systematic review with meta-analysis. European Journal of Cancer, 45, 1890–1896.CrossRef

61.

Benatti, P., Gafa, R., Barana, D., Marino, M., Scarselli, A., Pedroni, M., et al. (2005). Microsatellite instability and colorectal cancer prognosis. Clinical Cancer Research, 11, 8332–8340.CrossRefPubMed

62.

Kim, S. T., Lee, J., Park, S. H., Park, J. O., Lim, H. Y., Kang, W. K., et al. (2010). Clinical impact of microsatellite instability in colon cancer following adjuvant FOLFOX therapy. Cancer Chemotherapy and Pharmacology, 66, 659–667.CrossRefPubMed

63.

Des, G. G., Uzzan, B., Nicolas, P., Schischmanoff, O., Perret, G. Y., & Morere, J. F. (2009). Microsatellite instability does not predict the efficacy of chemotherapy in metastatic colorectal cancer. A systematic review and meta-analysis. Anticancer Research, 29, 1615–1620.

64.

Pegg, A. E. (1990). Mammalian O6-alkylguanine-DNA alkyltransferase: Regulation and importance in response to alkylating carcinogenic and therapeutic agents. Cancer Research, 50, 6119–6129.PubMed

65.

Gander, M., Leyvraz, S., Decosterd, L., Bonfanti, M., Marzolini, C., Shen, F., et al. (1999). Sequential administration of temozolomide and fotemustine: Depletion of O6-alkyl guanine-DNA transferase in blood lymphocytes and in tumours. Annals of Oncology, 10, 831–838.CrossRefPubMed

66.

Gerard, B., Aamdal, S., Lee, S. M., Leyvraz, S., Lucas, C., D’Incalci, M., et al. (1993). Activity and unexpected lung toxicity of the sequential administration of two alkylating agents—dacarbazine and fotemustine—in patients with melanoma. European Journal of Cancer, 29A, 711–719.CrossRefPubMed

67.

Quinn, J. A., Desjardins, A., Weingart, J., Brem, H., Dolan, M. E., Delaney, S. M., et al. (2005). Phase I trial of temozolomide plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. Journal of Clinical Oncology, 23, 7178–7187.CrossRefPubMed

68.

Ryan, C. W., Dolan, M. E., Brockstein, B. B., McLendon, R., Delaney, S. M., Samuels, B. L., et al. (2006). A phase II trial of O6-benzylguanine and carmustine in patients with advanced soft tissue sarcoma. Cancer Chemotherapy and Pharmacology, 58, 634–639.CrossRefPubMed

69.

Batts, E. D., Maisel, C., Kane, D., Liu, L., Fu, P., O’Brien, T., et al. (2007). O6-benzylguanine and BCNU in multiple myeloma: A phase II trial. Cancer Chemotherapy and Pharmacology, 60, 415–421.CrossRefPubMed

70.

Sabharwal, A., Corrie, P. G., Midgley, R. S., Palmer, C., Brady, J., Mortimer, P., et al. (2010). A phase I trial of lomeguatrib and irinotecan in metastatic colorectal cancer. Cancer Chemotherapy and Pharmacology, 66, 829–835.CrossRefPubMed

71.

Khan, O. A., Ranson, M., Michael, M., Olver, I., Levitt, N. C., Mortimer, P., et al. (2008). A phase II trial of lomeguatrib and temozolomide in metastatic colorectal cancer. British Journal of Cancer, 98, 1614–1618.CrossRefPubMed

72.

Watson, A. J., Middleton, M. R., McGown, G., Thorncroft, M., Ranson, M., Hersey, P., et al. (2009). O(6)-methylguanine-DNA methyltransferase depletion and DNA damage in patients with melanoma treated with temozolomide alone or with lomeguatrib. British Journal of Cancer, 100, 1250–1256.CrossRefPubMed

73.

Kefford, R. F., Thomas, N. P., Corrie, P. G., Palmer, C., Abdi, E., Kotasek, D., et al. (2009). A phase I study of extended dosing with lomeguatrib with temozolomide in patients with advanced melanoma. British Journal of Cancer, 100, 1245–1249.CrossRefPubMed

74.

Ranson, M., Hersey, P., Thompson, D., Beith, J., McArthur, G. A., Haydon, A., et al. (2007). Randomized trial of the combination of lomeguatrib and temozolomide compared with temozolomide alone in chemotherapy naive patients with metastatic cutaneous melanoma. Journal of Clinical Oncology, 25, 2540–2545.CrossRefPubMed

75.

Liu, L., Nakatsuru, Y., & Gerson, S. L. (2002). Base excision repair as a therapeutic target in colon cancer. Clinical Cancer Research, 8, 2985–2991.PubMed

76.

Zhu, Y., Hu, J., Hu, Y., & Liu, W. (2009). Targeting DNA repair pathways: A novel approach to reduce cancer therapeutic resistance. Cancer Treatment Reviews, 35, 590–596.CrossRefPubMed

77.

Haince, J. F., Rouleau, M., Hendzel, M. J., Masson, J. Y., & Poirier, G. G. (2005). Targeting poly(ADP-ribosyl)ation: A promising approach in cancer therapy. Trends in Molecular Medicine, 11, 456–463.CrossRefPubMed

78.

Drew, Y., & Plummer, R. (2009). PARP inhibitors in cancer therapy: Two modes of attack on the cancer cell widening the clinical applications. Drug Resistance Updates, 12, 153–156.CrossRefPubMed

79.

Farmer, H., McCabe, N., Lord, C. J., Tutt, A. N., Johnson, D. A., Richardson, T. B., et al. (2005). Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy. Nature, 434, 917–921.CrossRefPubMed

80.

Fong, P. C., Boss, D. S., Carden, C. P., Roelvink, M., DeGreve, J., Gourley, C. M., et al. (2008). AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study. Journal of Clinical Oncology, 26, abstr 5510.

81.

Audeh, M. W., Penson, R. T., Friedlander, M., Powell, B., Bell-McGuinn, K. M., Scott, C., et al. (2009). Phase II trial of the oral PARP inhibitor olaparib (AZD2281) in BRCA-deficient advanced ovarian cancer. Journal of Clinical Oncology, 27, abstr 5500.

82.

Tutt, A., Robson, M., Garber, E., Domchek, S., Audeh, M. W., Weitzel, J. N., et al. (2009). Phase II trial of the oral PARP inhibitor olaparib in BRCA-deficient advanced breast cancer. Journal of Clinical Oncology, 27, abstr CRA501.

83.

Plummer, R., Lorigan, P., Evans, J., Steven, N., Middleton, M., Wilson, R., et al. (2006). First and final report of a phase II study of the poly(ADP-ribose) polymerase (PARP) inhibitor, AG014699, in combination with temozolomide (TMZ) in patients with metastatic malignant melanoma (MM). Journal of Clinical Oncology, 24, abstr 8013.

84.

Bedikian, A. Y., Papadopoulos, N. E., Kim, K. B., Hwu, W. J., Homsi, J., Glass, M. R., et al. (2009). A phase IB trial of intravenous INO-1001 plus oral temozolomide in subjects with unresectable stage-III or IV melanoma. Cancer Investigation, 27, 756–763.CrossRefPubMed

85.

Kummar, S., Kinders, R., Gutierrez, M. E., Rubinstein, L., Parchment, R. E., Phillips, L. R., et al. (2009). Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies. Journal of Clinical Oncology, 27, 2705–2711.CrossRefPubMed

86.

Plummer, R., Jones, C., Middleton, M., Wilson, R., Evans, J., Olsen, A., et al. (2008). Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clinical Cancer Research, 14, 7917–7923.CrossRefPubMed

87.

Fong, P. C., Boss, D. S., Yap, T. A., Tutt, A., Wu, P., Mergui-Roelvink, M., et al. (2009). Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers. The New England Journal of Medicine, 361, 123–134.CrossRefPubMed

Titel: DNA repair pathways and their implication in cancer treatment
verfasst von: Athanasios G. Pallis
Michalis V. Karamouzis
Publikationsdatum: 01.12.2010
Verlag: Springer US
Erschienen in: Cancer and Metastasis Reviews / Ausgabe 4/2010
Print ISSN: 0167-7659
Elektronische ISSN: 1573-7233
DOI: https://doi.org/10.1007/s10555-010-9258-8

Neu im Fachgebiet Onkologie

19.04.2024 | EAU 2024 | Kongressbericht | Nachrichten

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

DNA repair pathways and their implication in cancer treatment

Abstract

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 4/2010

Minimizing early relapse and maximizing treatment outcomes in hormone-sensitive postmenopausal breast cancer: efficacy review of AI trials

DNA methylation or histone modification status in metastasis and angiogenesis-related genes: a new hypothesis on usage of DNMT inhibitors and S-adenosylmethionine for genome stability

Feedback regulation of proteasome gene expression and its implications in cancer therapy

Distant metastases do not metastasize

Cytochrome P450-derived eicosanoids: the neglected pathway in cancer

Perspectives on the mesenchymal origin of metastatic cancer

Neu im Fachgebiet Onkologie

Prostatakarzinom: EU initiiert neues Screeningkonzept

Blasenkarzinom – Biomarker statt Zytologie?

Stereotaktische Radiatio schlägt konventionelle Bestrahlung

Adjuvante Brustkrebstherapie: Doppelt hält besser

Update Onkologie